AC Immune Ltd - Asset Resilience Ratio
AC Immune Ltd (ACIU) has an Asset Resilience Ratio of 41.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of AC Immune Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how AC Immune Ltd's Asset Resilience Ratio has changed over time. See net assets of AC Immune Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down AC Immune Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACIU stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $64.69 Million | 41.89% |
| Total Liquid Assets | $64.69 Million | 41.89% |
Asset Resilience Insights
- Very High Liquidity: AC Immune Ltd maintains exceptional liquid asset reserves at 41.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AC Immune Ltd Industry Peers by Asset Resilience Ratio
Compare AC Immune Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for AC Immune Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for AC Immune Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.89% | $64.69 Million | $154.43 Million | -14.07pp |
| 2024-12-31 | 55.96% | $129.21 Million | $230.91 Million | +42.53pp |
| 2023-12-31 | 13.43% | $24.55 Million | $182.81 Million | -35.51pp |
| 2022-12-31 | 48.94% | $91.00 Million | $185.94 Million | +4.57pp |
| 2021-12-31 | 44.37% | $116.00 Million | $261.44 Million | +17.14pp |
| 2020-12-31 | 27.23% | $65.00 Million | $238.74 Million | -4.52pp |
| 2019-12-31 | 31.75% | $95.00 Million | $299.25 Million | +16.48pp |
| 2018-12-31 | 15.26% | $30.00 Million | $196.56 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $132.01 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $156.10 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $79.93 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $30.30 Million | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more